Press Releases

Press Releases

Indi® Secures Contracts for Xpresys® Lung with Multiplan and Five Other PPOs; Blood Test for Pulmonary Nodules Now Available to 200 Millon Covered Lives
5 November 2014
Indi® (Integrated Diagnostics), an emerging leader in molecular diagnostics, today announced that the company has secured contractual agreements with MultiPlan and five other PPOs (preferred provider organizations) for Xpresys® Lung, the first non-invasive molecular blood test for the assessment of pulmonary nodules. The other PPOs are: FedMed, Fortified Provider Network, InterWest Health, Stratose, and Three Rivers Provider Network. Together, these managed care organizations provide access to more than 130 million insured lives; combined with Indi’s existing commercial insurance contracts the test is now available to well over 200 million insured lives. more

Indi® Announces Early Data Supporting Xpresys® Lung To Be Presented At ATS 2014
16 May 2014
Indi (Integrated Diagnostics), a molecular diagnostics company pioneering the use of blood-based proteomic tests, announced today that preliminary data supporting Xpresys Lung – and characterizing decision-making in the management of lung nodules – will be presented at the American Thoracic Society (ATS) 2014 International Conference taking place May 16-21, 2014 in San Diego. more

Indi® Announces $47.25 Million In Funding For Blockbuster Diagnostic
29 April 2014
Indi (Integrated Diagnostics), a molecular diagnostics company pioneering the use of blood-based proteomic tests, announced today it has raised $30.25 million from the closing of its Series B and $17 million in non-dilutive debt financing provided by Life Sciences Alternative Funding LLC (LSAF). The financing round was led by Baird Capital and joined by Indi’s existing investors, InterWest Partners and the Wellcome Trust … more

Indi® Announces Availability of Xpresys™ Lung Blood Test With Potential To Help Physicians Identify More Lung Nodules As Likely Benign And More Patients As Possible Candidates For Active Surveillance Instead of Invasive Procedures
28 October 2013
Indi (Integrated Diagnostics), an emerging leader in molecular diagnostics, today announced the availability of Xpresys Lung, a protein expression blood test with the potential to help physicians diagnose more lung nodules as likely benign, thereby increasing the number of patients who can confidently choose serial CT scans of their nodules (“active surveillance”), instead of invasive procedures like surgery and biopsy, … more

Study Suggests Indi Blood Test Can Differentiate Between Benign Lung Nodules & Early Stage Lung Cancer
16 October 2013
Indi (Integrated Diagnostics), an emerging leader in molecular diagnostics, today announced the results of a major study which suggests that quantifying a combination of blood proteins can distinguish between benign lung nodules and early-stage lung cancer with high probability. The study, which was published today in Science Translational Medicine (STM), suggests that when this group of proteins (or ‘classifier’) is detected, … more

Indi Molecular Launches with Pre-eminent Team to Develop Replacement for Antibodies
20 September 2013
Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised a $1.5 million seed round led by InterWest Partners and joined by several angel investors. The funds will be used to further develop PCC (protein catalyzed capture) agent technology… more

Integrated Diagnostics® Appoints CFO & VP Sales Prior to Launch of Lung Cancer Diagnostic
6 March 2013
John Bencich Appointed Chief Financial Officer; Jill Tonachio is Vice President for Sales SEATTLE — Integrated Diagnostics (Indi®), an emerging leader in molecular diagnostics, today announced that it has appointed John Bencich as chief financial officer and Jill Tonachio as vice president for sales. The two executives will play key roles in the launch of… more

Integrated Diagnostics® Launches Imaging Division to Create PET Imaging Probes
13 June 2012
Dr. Norman Hardman is Appointed President of InDi Imaging™ Dr. Michael Phelps, Inventor of PET Technology, is Appointed Advisor SEATTLE – Integrated Diagnostics (InDi®), an emerging leader in molecular diagnostics, today announced that the company has launched a new operating division, InDi Imaging™, that is creating a new generation of PET imaging probes using the… more

Integrated Diagnostics® Secures $10 Million Third Tranche of Series A Financing; Company Appoints CFO and CBO, Completing Executive Team
22 February 2012
SEATTLE – Integrated Diagnostics (InDi®), an emerging leader in molecular diagnostics, today announced that the company has made substantial progress in its diagnostic programs, triggering a $10 million third tranche of its Series A financing. The company will use the funds to complete clinical development of its in vitro proteomic-based diagnostics programs and prepare for… more

Agilent Technologies and Integrated Diagnostics Enter Strategic Partnership to Develop Protein-Based Assays for Early Disease Detection
10 January 2012
SANTA CLARA, Calif., and SEATTLE, Wash., – Agilent Technologies Inc. (NYSE: A) and Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes. Integrated Diagnostics, an emerging leader in molecular diagnostics, is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics… more

Caltech and Integrated Diagnostics Researchers Receive Grand Challenges Point-of-Care Diagnostics Grant
16 December 2011
SEATTLE –– Integrated Diagnostics announced today that researchers from the company and the California Institute of Technology (Caltech) will receive a Point- of-Care Diagnostics grant through Grand Challenges in Global Health, an initiative created by the Bill & Melinda Gates Foundation that seeks to engage creative minds across scientific disciplines — including those who have not… more

Integrated Diagnostics and Caltech Researchers Jointly Create Synthetic Class of Diagnostics and Therapeutic Agents with Antibody-Like Properties
26 October 2011
Protein-Catalyzed Capture Agents (PCCs) Designed Using “Click Chemistry” Show Promise for Broad Use in Diagnostics and Therapeutics Data Demonstrating Synthetic Class of Site-Specific Binding Molecules is Published in the Journal of the American Chemical Society SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics, today announced that it has created a synthetic class of… more

Integrated Diagnostics Licenses “Click Chemistry” From The Scripps Research Institute, Strengthening Partner Network
26 October 2011
Dr. Barry Sharpless, Nobel Laureate and Click Chemistry Pioneer, Joins Integrated Diagnostics as Advisor SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics, today announced that it has signed a worldwide licensing agreement with The Scripps Research Institute, strengthening its growing network of partners. Under the license, the company will have access to “click… more

Integrated Diagnostics Appoints Jay Moyes to Board of Directors
9 March 2011
Past CFO of Myriad Genetics Joins Preeminent Team at Dr. Lee Hood-Founded Molecular Diagnostics Company SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics founded by Lee Hood, M.D., Ph.D., today announced that Jay Moyes has joined the company’s Board as an independent director. Moyes is the past chief financial officer of Myriad Genetics… more

Integrated Diagnostics Appoints Dr. Kenneth C. Fang Chief Medical Officer
26 January 2011
New CMO to lead rapid development and commercialization of blood-based diagnostics for lung cancer and Alzheimer’s disease SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics founded by Lee Hood, M.D., Ph.D., today announced that Kenneth C. Fang, M.D., has been appointed chief medical officer and vice president of translational research and clinical development… more

Dr. Gregory Critchfield Joins Integrated Diagnostics Board of Directors
5 October 2010
Past President of Myriad Genetic Laboratories Joins Preeminent Team at Dr. Lee Hood-Founded Molecular Diagnostics Company SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics founded by Lee Hood, M.D., Ph.D., today announced that Gregory Critchfield, M.D., M.S., has joined the company’s Board as an independent director. Dr. Critchfield is the past president of… more

Integrated Diagnostics Secures $10 Million Second Tranche of Series A Financing
22 July 2010
Substantial Progress Made in Developing Blood-Based Proteomic Diagnostics; BioTechCube Luxembourg Joins Series A Investors; New Board Member Appointed SEATTLE – Integrated Diagnostics, an emerging leader in personalized diagnostics founded by Dr. Leroy Hood, today announced that the company has made substantial progress, triggering a $10 million second tranche of its Series A financing. The funds… more

Integrated Diagnostics Appoints Dr. Albert Luderer to Serve as CEO
29 March 2010
Senior Life Sciences Executive Will Lead Emerging Personalized Diagnostics Company Founded by Dr. Leroy Hood SEATTLE – Integrated Diagnostics, a personalized diagnostics company founded by Dr. Leroy Hood, today announced that Dr. Albert Luderer has been appointed by the Board of Directors to serve as CEO. Dr. Luderer was previously president and CEO of BioTrove,… more

Integrated Diagnostics Launches with Pre-eminent Team and Investors
14 October 2009
Dr. Leroy Hood-led venture secures $30 million Series A financing from InterWest Partners, Wellcome Trust and dievini SEATTLE – Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will… more

 
 

Join Our Mailing List:

219 Terry Avenue North Suite 100

Seattle, WA 98109-5208

Phone: 206.576.6300

Fax: 206.576.6350


Xpresys Lung

Customer Support Phone:

855.977.3797 or 855.XPRESYS

Email: info@indidx.com

Follow Us

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue